Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02953509 · ClinicalTrials.gov registry record · Phase 1
Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 178
- Enrollment target
NCT02953509 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 178 participants.
The verdict
NCT02953509, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 178 participants
- Enrollment target
Study Summary
The primary objectives of this study are: * To investigate the safety and tolerability, and to define the recommended Phase 2 dose and schedule (RP2DS) for magrolimab in combination with rituximab and for magrolimab in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx). * To evaluate the efficacy of magrolimab in combination with rituximab in participants with indolent lymphoma and diffuse large B-cell lymphoma (DLBCL) and to evaluate the efficacy of magrolimab in combination with R-GemOx in autologous stem cell transplant (ASCT) ineligible DLBCL participants.
Interventions
- DRUG Oxaliplatin
- DRUG Rituximab
- DRUG Gemcitabine
- DRUG Allopurinol
- DRUG Magrolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2016-11-21 |
| Est. Completion | 2024-03-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02953509
The ClinicalTrials.gov registry entry for NCT02953509 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Oxaliplatin is the first listed.
NCT02953509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02953509 about?
NCT02953509 is a clinical study titled "Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma". The primary objectives of this study are: * To investigate the safety and tolerability, and to define the recommended Phase 2 dose and schedule (RP2DS) for magrolimab in combination with rituximab and for magrolimab in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx). * To evaluat...
What is the current status of trial NCT02953509?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 178 participants. The study started on 2016-11-21. Estimated completion is 2024-03-25.
What interventions are being tested in trial NCT02953509?
The interventions under investigation include: Oxaliplatin (DRUG), Rituximab (DRUG), Gemcitabine (DRUG), Allopurinol (DRUG), Magrolimab (DRUG).
Who is sponsoring clinical trial NCT02953509?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.